4Filed Sep 1, 8:00 PM ET

Gilead CEO Daniel O'Day Sells 15,000 Shares

$GILD · GILEAD SCIENCES, INC.

Research Summary

AI-generated summary of this SEC filing

Updated

Gilead CEO Daniel O'Day Sells 15,000 Shares

What Happened
Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences (GILD), reported three open-market sales on 2026-09-01 totaling 15,000 shares for aggregate proceeds of $2,229,592. The reported per‑share prices on the Form 4 were $147.51 (1,600 shares, $236,014), $148.36 (7,992 shares, $1,185,722) and $149.38 (5,408 shares, $807,856). These were outright sales (not purchases or option exercises).

Key Details

  • Transaction date: 2026-09-01 (filed with the SEC on 2026-09-02; filing appears timely).
  • Reported trades:
    • 1,600 shares @ $147.51 = $236,014
    • 7,992 shares @ $148.36 = $1,185,722
    • 5,408 shares @ $149.38 = $807,856
  • Total shares sold: 15,000; total proceeds: $2,229,592.
  • Footnotes:
    • F1: Trades were made pursuant to a Rule 10b5-1 trading plan adopted Feb 25, 2026.
    • F2–F4: Indicate sale-price ranges for the reported lots (approx. $146.94–$149.94); the filing notes detailed per-price breakdowns are available on request.
  • Shares owned after the transaction: not specified in this Form 4.

Context
Sales conducted under a Rule 10b5-1 plan are pre-scheduled and routine for insiders managing liquidity, diversification, or tax planning; they do not by themselves indicate a change in the insider’s view of the company. This filing reports simple open-market sales (code S) rather than option exercises, grants, or gifts.